Soligenix Inc (SNGX)
NASDAQ:SNGX
SNGX Stock Chart & Stats
$1.44
-$0.10(-2.65%)
At close: 4:00 PM EST
$1.44
-$0.10(-2.65%)
Day’s Range― - ―
52-Week Range$1.00 - $6.23
Previous CloseN/A
Volume55.16K
Average Volume (3M)268.40K
Market Cap
$11.75M
Enterprise Value$3.92M
Total Cash (Recent Filing)$7.94M
Total Debt (Recent Filing)$358.14K
Price to Earnings (P/E)―
Beta0.27
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.32
Shares Outstanding10,306,079
10 Day Avg. Volume532,707
30 Day Avg. Volume268,403
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.68
Enterprise Value/Market Cap0.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.58K
Enterprise Value/Ebitda-0.33
Forecast
1Y Price Target
$10.00Price Target Upside594.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.85
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Orphan And Regulatory Designations For SGX945EMA/EC orphan designation and related UK/US designations create durable regulatory incentives (10-year EU exclusivity, protocol assistance, centralized review access). These structural protections raise commercial optionality and partnership appeal for a small biotech pursuing rare-disease approvals.
FLASH2 Phase 3 Enrollment ProgressAdvancing enrollment with blinded responses exceeding design assumptions materially de-risks clinical development. A successful interim in Q2 2026 could validate efficacy, shorten timelines, and increase partner interest, improving long-term commercialization prospects for HyBryte across cutaneous indications.
Improved Leverage And Available CapitalMarked reduction in debt and positive equity rebuild improves financial flexibility versus earlier periods. With roughly $11M cited to support operations through 2026, the company has a clearer runway to reach near-term clinical milestones, lowering immediate insolvency risk and enabling strategic partnership talks.
Bears Say
Effectively Zero Product RevenueAs a pre‑commercial biotech, Soligenix lacks recurring product revenue, leaving operations fully reliant on grants, collaborations and financing. Persistent absence of sales limits ability to self-fund R&D, prolongs dependence on capital markets, and increases execution risk over the medium term.
Rising Cash Burn And Negative Operating Cash FlowWorsening operating cash flow and accelerating cash burn indicate the business cannot sustain development from operations. That structural cash deficit pressures timelines, compresses runway absent financing, and forces management to prioritize fundraising over long‑term optionality or broader indication expansion.
Dependence On Equity Financing; Dilution RiskThe ATM facility provides flexible access to capital but signals ongoing reliance on equity markets. Regular or opportunistic share issuance can materially dilute existing holders and reflects that internal cash generation is insufficient to fund pivotal trials without potentially dilutive financing.
Soligenix News
SNGX FAQ
What was Soligenix Inc’s price range in the past 12 months?
Soligenix Inc lowest stock price was $1.00 and its highest was $6.23 in the past 12 months.
What is Soligenix Inc’s market cap?
Soligenix Inc’s market cap is $11.75M.
When is Soligenix Inc’s upcoming earnings report date?
Soligenix Inc’s upcoming earnings report date is May 08, 2026 which is in 34 days.
How were Soligenix Inc’s earnings last quarter?
Soligenix Inc released its earnings results on Mar 31, 2026. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of -$0.26 by $0.58.
Is Soligenix Inc overvalued?
According to Wall Street analysts Soligenix Inc’s price is currently Undervalued.
Does Soligenix Inc pay dividends?
Soligenix Inc does not currently pay dividends.
What is Soligenix Inc’s EPS estimate?
Soligenix Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Soligenix Inc have?
Soligenix Inc has 10,306,079 shares outstanding.
What happened to Soligenix Inc’s price movement after its last earnings report?
Soligenix Inc reported an EPS of $0.32 in its last earnings report, beating expectations of -$0.26. Following the earnings report the stock price went up 6.306%.
Which hedge fund is a major shareholder of Soligenix Inc?
Currently, no hedge funds are holding shares in SNGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Soligenix Inc
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
SNGX Stock 12 Month Forecast
Average Price Target
$10.00
▲(594.44% Upside)
Technical Analysis
Ownership Overview
3.86% Insiders
0.68% Mutual Funds
1.61% Other Institutional Investors
93.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---